Skip to content

In-use Tolerance and Efficacy Study Under Dermatological and Ophthalmological Controls - Face Cream, RV4983A - LA3365

In-use Tolerance and Efficacy Study Under Dermatological and Ophthalmological Controls - Face Cream, RV4983A - LA3365

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07208227
Enrollment
44
Registered
2025-10-06
Start date
2021-10-27
Completion date
2022-02-07
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep Wrinkles, Healthy, Sensitive Skin

Keywords

open trial, antiaging cosmetic cream

Brief summary

Tolerance and efficacy study of an anti aging cream on 44 subjects aged between 45 and 65 years, with sensitive skin and deep wrinkles. This study is conducted as a national, monocentric, non-randomized open trial. Planning of the visits: * Visit 1: Inclusion (Day 1) * Visit 2: Intermediate visit (Day 29), a window of +48 hours is allowed * Visit 3: End of study (Day 57), a window of +72 hours is allowed The maximum duration of participation for a subject is 60 days.

Interventions

OTHERFace Cream RV4983A LA3365

Cosmetic face cream product applied once a day on face, neck and neckline.

Sponsors

Pierre Fabre Dermo Cosmetique
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
45 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

Criteria related to the population: * female * aged between 45 and 65 years included * phototype: I to III * skin type: oily, combination, normal, dry, very dry * 100% of subjects with sensitive skin on the face * 100% of subjects with deep wrinkles on the face * 100% of subjects with sagging skin on the face * 100% of subjects with dull and uneven complexion * subjects must be registered with health social security or health social insurance * having signed their written Informed Consent form (ICF) for their participation in the study and a photograph authorization * certifying the truth of the personal information declared to the Investigator * able to understand the language used in the investigation centre and the information given * able to comply with the protocol and follow protocol's constraints and specific requirements * a maximum of 20% of subjects being lens wearers will be included in the study * subject agree to not expose herself to sunlight or UV during the study and if necessary, provide sun protection Criteria related to subject's health: * considered healthy subject by the Investigator * women of childbearing potential committing themselves to use effective contraceptive method throughout the study and for at least 3 months before the inclusion visit NON INCLUSION CRITERIA Criteria related to the population: * having participated in another clinical trial within the week before the inclusion visit and for a longer period if required in the Investigator's opinion * taking part or planning to participate in another clinical trial during the study in the same or another investigation centre * deprived of freedom by administrative or legal decision or under guardianship * not able to be contacted in case of emergency * admitted in a sanitary or social facilities o planning an hospitalization during the study * belonging to the staff of the investigation centre Criteria related to subject's health: * breastfeeding, pregnant (for the women of childbearing potential) * having a dermatological condition liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements * having an ophthalmological condition liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements * having personal medical history liable to interfere with the study data for the subject (especially characterized cosmetic hyperreactivity) or incompatible with the study requirements (except if this population is required by the Sponsor i.e atopic dermatitis) * having history of abnormal reactions from exposure to sunlight * having taken any previous treatment considered by the Investigator liable to interfere with the study data or incompatible with the study requirements * being under any treatment considered by the Investigator liable to interfere with the study data or incompatible with the study requirements Criteria related to investigational product application areas: * having had any surgery, chemical or significant invasive dermo-treatment on the experimental area considered by the Investigator liable to interfere with the study data, before the inclusion visit or foreseeing it for the duration of the study * having applied a skincare or make up product on the study areas the day of the inclusion visit. The usual cleanser is allowed. * having received, on the study areas, artificial UV exposure or excessive exposure to natural sunlight within the 1 month before the inclusion visit Criteria related to the COVID-19 pandemic: * Subject who was abroad in a country with a higher incidence rate of Covid-19 than Poland, within 14 days before the beginning of the study * Subject presenting following symptoms: cough, shortness of breath, elevated body temperature - equal or above 37,5°C * Subject who had contact with any person infected with COVID-19 within 10 days before the beginning of the study * Subject who is currently during home quarantine recommended by the Sanitary Inspection

Design outcomes

Primary

MeasureTime frameDescription
Global tolerance assessmentAt the end of the study, after Last Patient Out, (after Day 57)Global tolerance is assessed on the tolerance population which includes all the subjects who applied at least once investigational product. Global assessment of the dermatological and ophthalmological tolerance is done by the investigator. This assessment allows for attribution of one of the 5 levels : excellent, very good, good, moderate, bad.

Secondary

MeasureTime frameDescription
Rz parameter to evaluate smoothing/anti-wrinkle effectVisit 1 (Day 1, before investigational product application), Visit 2 (Day 29) and Visit 3 (Day 57).Rz= Average height of the roughness= Average relief Rz is the average of 5 single roughness depths, measured within the section ln. The single roughness depth is the difference from the highest profile peak to the deepest profile valley within a single measurement section. Measured by 3D PRIMOS-CR SYSTEM
Rt parameter to evaluate smoothing/anti-wrinkle effectVisit 1 (Day 1, before investigational product application), Visit 2 (Day 29) and Visit 3 (Day 57).Rt= Maximum height of the roughness profile= maximum relief amplitude Rt is the height difference from the highest peak to the deepest valley within the total measurement section Measured by 3D PRIMOS-CR SYSTEM
Clinical scoring of the visibility of crow's feet wrinklesVisit 1 (Day 1, before investigational product application), Visit 2 (Day 29) and Visit 3 (Day 57).Assessed by the investigator according to the BAZIN scale (7-point scale, from 0 to 6)
Clinical scoring of the Smoothness of the skinVisit 1 (Day 1, before investigational product application), Visit 2 (Day 29) and Visit 3 (Day 57).Assessed by the investigator on a 11-point scale (0 = rough skin, 10 = very smooth skin)
Clinical scoring of the Firmness of the skinVisit 1 (Day 1, before investigational product application), Visit 2 (Day 29) and Visit 3 (Day 57).Assessed by the investigator on a 11-point scale (0 = sagged skin, 10 = very firm skin)
Ra parameter to evaluate smoothing/anti-wrinkle effectVisit 1 (Day 1, before investigational product application), Visit 2 (Day 29) and Visit 3 (Day 57).Ra= Average roughness Ra is the arithmetic mean of the absolute values (without differentiation between peaks and valleys) of the heights of the profile length. Measured by 3D PRIMOS-CR SYSTEM
Clinical scoring of Radiance/ Luminosity based on photographsVisit 1 (Day 1, before investigational product application), Visit 2 (Day 29) and Visit 3 (Day 57).Assessed by three jury assessors who assess the parameter on unstructured scales (corresponding to scores from 0 to 10, 0= dull, 10= radiant/luminous) based on photographs taken by Colorface
Clinical scoring of Skin brightness based on photographsVisit 1 (Day 1, before investigational product application), Visit 2 (Day 29) and Visit 3 (Day 57).Assessed by three jury assessors who assess the parameter on unstructured scales (corresponding to scores from 0 to 10, 0= not bright at all, 10= very bright) based on photographs taken by Colorface
Clinical scoring of homogeneity of skin tone based on photographsVisit 1 (Day 1, before investigational product application), Visit 2 (Day 29) and Visit 3 (Day 57).Assessed by three jury assessors who assess the parameter on unstructured scales (corresponding to scores from 0 to 10, 0= not even at all, 10= very even) based on photographs taken by Colorface
Clinical scoring of homogeneity of skin texture based on photographsVisit 1 (Day 1, before investigational product application), Visit 2 (Day 29) and Visit 3 (Day 57).Assessed by three jury assessors who assess the parameter on unstructured scales (corresponding to scores from 0 to 10, 0= coarse, 10= fine) based on photographs taken by Colorface
Clinical scoring of the Skin plumpnessVisit 1 (Day 1, before investigational product application), Visit 2 (Day 29) and Visit 3 (Day 57).Assessed by the investigator on a 11-point scale (0 = thin and not replumped skin, 10 = very replumped skin)

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026